Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2009

The Pharma Closeout tracks 35 deals, $196.6B in disclosed deal value, 31 with a post-close Outcome Score for the year 2009.

Median Critic Score: 83  ·  Median Outcome Score: 62

Best outcome: Astellas Pharma Inc. / Seagen Inc. (95)  ·  Weakest outcome: Sanofi-Aventis / BiPar Sciences, Inc. (8)

All 35 deals

• Astellas Pharma Inc. / Seagen Inc. — 2009 · $4.5B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Medarex Inc. — 2009 · $2.4B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Cougar Biotechnology, Inc. — 2009 · $970M · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Wyeth — 2009 · $68.0B · Worked — the deal delivered on its rationale.
• QIAGEN N.V. / DxS Ltd. — 2009 · $130M · Worked — the deal delivered on its rationale.
• Sigma-Tau Group / Enzon Pharmaceuticals (Specialty Pharma business) — 2009 · $327M · Worked — the deal delivered on its rationale.
• Watson Pharmaceuticals, Inc. / Arrow Group — 2009 · $1.8B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Genentech, Inc. — 2009 · $46.8B · Largely worked — most objectives met.
• Merck & Co. Inc. / Schering-Plough Corp. — 2009 · $41.1B · Largely worked — most objectives met.
• Eli Lilly and Company / Incyte Corporation — 2009 · $755M · Largely worked — most objectives met.
• Valeant Pharmaceuticals International / Dow Pharmaceutical Sciences, Inc. — 2009 · $285M · Largely worked — most objectives met.
• Sanofi-Aventis / Merial Limited (Merck's 50% interest) — 2009 · $4.0B · Largely worked — most objectives met.
• GSK plc / Stiefel Laboratories — 2009 · $3.6B · Largely worked — most objectives met.
• Sanofi SA / Chattem Inc. — 2009 · $1.9B · Largely worked — most objectives met.
• Dainippon Sumitomo Pharma Co., Ltd. / Sepracor Inc. — 2009 · $2.6B · Largely worked — most objectives met.
• Gilead Sciences Inc. / CV Therapeutics Inc. — 2009 · $1.4B · Largely worked — most objectives met.
• Boehringer Ingelheim Vetmedica, Inc. / Wyeth/Fort Dodge Animal Health (divested assets) — 2009 · Largely worked — most objectives met.
• AstraZeneca plc / Novexel S.A. — 2009 · $505M · Mixed — partial payoff, real shortfalls.
• Cubist Pharmaceuticals, Inc. / Calixa Therapeutics, Inc. — 2009 · $402M · Mixed — partial payoff, real shortfalls.
• Abbott Laboratories / Solvay Pharmaceuticals (Solvay Group) — 2009 · $6.6B · Mixed — partial payoff, real shortfalls.
• Reig Jofre / Bioglan — 2009 · Mixed — partial payoff, real shortfalls.
• Celgene Corporation / Gloucester Pharmaceuticals, Inc. — 2009 · $640M · Underwhelmed — fell short of the thesis.
• Sanofi-Aventis (Sanofi Pasteur) / Shantha Biotechnics Limited — 2009 · $784M · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / Genmab A/S (HuMax-TAC follow-on) — 2009 · $102M · Underwhelmed — fell short of the thesis.
• Endo Pharmaceuticals Holdings, Inc. / Indevus Pharmaceuticals, Inc. — 2009 · $370M · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / Stiefel Laboratories, Inc. — 2009 · $3.6B · Did not work — the deal failed to deliver.
• Sanofi-Aventis / Fovea Pharmaceuticals SA — 2009 · $541M · Did not work — the deal failed to deliver.
• Hospira, Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (Generic Injectables business) — 2009 · $400M · Did not work — the deal failed to deliver.
• Cephalon Inc. / Arana Therapeutics Limited — 2009 · $203M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Insmed Inc. (Follow-on Biologics platform) — 2009 · $130M · Did not work — the deal failed to deliver.
• Sanofi-Aventis / BiPar Sciences, Inc. — 2009 · $500M · Did not work — the deal failed to deliver.
• Roche Holding AG / Plexxikon Inc. — 2009 · $335M
• Bayer AG (Bayer HealthCare) / Algeta ASA — 2009 · $800M
• Pfizer Inc. / Protalix BioTherapeutics, Inc. — 2009 · $175M
• GlaxoSmithKline plc / Concert Pharmaceuticals, Inc. — 2009 · $35M

← Deal Library  ·  Interactive search  ·  How we score deals